A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Phase 2
Active, not recruiting
NCT04624178
| Condition | Leiomyosarcoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 20 participants |
|---|
| Interventions | Rucaparib, Nivolumab |
|---|
| Start date | Nov 5, 2020 |
|---|
| Completion date | Nov 17, 2025 |
|---|
| Results posted | Jul 17, 2026 |
|---|
Summary
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Best Objective Response Rate
by 24 weeks · percentage of participants
| Rucaparib in Combination With Nivolumab | 5 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.